Clinical trial
PD-1 Monoclonal Antibody Camrelizumab Combined With Albumin Paclitaxel and Platinum for Neoadjuvant Treatment of Adcanced Esophageal Squamous Cell Carcinoma (ESCC): A Single-center, Single-arm Phase II Clinical Study
NCT04767295 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- PD-1 Monoclonal Antibody Camrelizumab Combined With Albumin Paclitaxel and Platinum for Neoadjuvant Treatment of Adcanced Esophageal Squamous Cell Carcinoma (ESCC): A Single-center, Single-arm Phase II Clinical Study
- Lead sponsor
- Hunan Cancer Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 1, 2021
- Completion date
- March 1, 2023
- Enrollment
- 28 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.